Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14749041 | 0.83 | PIK3CD (0.34) | PIK3CDTLR9TLR8TLR7L3MBTL1 | |
| SCHEMBL15569181 | 0.83 | PIK3CD (0.34) | PIK3CDTLR9TLR8TLR7L3MBTL1 | |
| SCHEMBL14752954 | 0.80 | PIK3CD (0.33) | PIK3CDTLR9TLR8TLR7L3MBTL1 | |
| SCHEMBL14752953 | 0.79 | CHRNB2 (0.37) | PIK3CDTLR9TLR8TLR7L3MBTL1 | |
| SCHEMBL21900166 | 0.79 | CHRNB2 (0.37) | PIK3CDTLR9TLR8TLR7SMN1; SMN2 | |
| SCHEMBL9441 | 0.75 | SMN1; SMN2 (0.34) | EPHX1SMN1; SMN2KDM4EATM | |
| SCHEMBL31111469 | 0.74 | SMN1; SMN2 (0.33) | EPHX1PIK3CDSMN1; SMN2KDM4E | |
| SCHEMBL20011843 | 0.74 | SLC6A3 (0.30) | — | |
| Hydrochloric Acid SCHEMBL4621413 | 0.73 | SMN1; SMN2 (0.33) | EPHX1SMN1; SMN2KDM4EATM | |
| SCHEMBL28564561 | 0.70 | SMN1; SMN2 (0.39) | EPHX1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SNCA, HTT, CLN6 | EPHX1 984/4885PIK3CD 2363/4885TLR9 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.